Compendium of Cancer Genome Aberrations

Changes

EYE5:Volunteer Assignments and Opportunities (view source)

Revision as of 13:02, 24 December 2023

3,005 bytes removed ,  13:02, 24 December 2023
no edit summary
Line 19: Line 19:  
!'''Notes'''
 
!'''Notes'''
 
|- |Usual ductal hyperplasia||Disease||
 
|- |Usual ductal hyperplasia||Disease||
−
|Usual Ductal Hyperplasia
+
|
 
|Disease
 
|Disease
 
|
 
|
Line 27: Line 27:  
|
 
|
 
|-
 
|-
−
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 36: Line 36:  
|
 
|
 
|-
 
|-
−
|Atypical Ductal Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 45: Line 45:  
|
 
|
 
|-
 
|-
−
|Sclerosing Adenosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 54: Line 54:  
|
 
|
 
|-
 
|-
−
|Apocrine Adenosis and Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 63: Line 63:  
|
 
|
 
|-
 
|-
−
|Microglandular Adenosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 72: Line 72:  
|
 
|
 
|-
 
|-
−
|Radial Scar/Complex Sclerosing Lesion||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 81: Line 81:  
|
 
|
 
|-
 
|-
−
|Tubular Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 90: Line 90:  
|
 
|
 
|-
 
|-
−
|Lactating Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 99: Line 99:  
|
 
|
 
|-
 
|-
−
|Ductal Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 108: Line 108:  
|
 
|
 
|-
 
|-
−
|Pleomorphic Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 117: Line 117:  
|
 
|
 
|-
 
|-
−
|Adenomyoepithelioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 126: Line 126:  
|
 
|
 
|-
 
|-
−
|Malignant Adenomyoepithelioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 135: Line 135:  
|
 
|
 
|-
 
|-
−
|Intraductal Papilloma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 144: Line 144:  
|
 
|
 
|-
 
|-
−
|Papillary Ductal Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 153: Line 153:  
|
 
|
 
|-
 
|-
−
|Encapsulated Papillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 162: Line 162:  
|
 
|
 
|-
 
|-
−
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 171: Line 171:  
|
 
|
 
|-
 
|-
−
|Invasive Papillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 180: Line 180:  
|
 
|
 
|-
 
|-
−
|Atypical Lobular Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 189: Line 189:  
|
 
|
 
|-
 
|-
−
|Lobular Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 198: Line 198:  
|
 
|
 
|-
 
|-
−
|Ductal Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 207: Line 207:  
|
 
|
 
|-
 
|-
−
|Invasive Breast Carcinoma of No Special Type||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 216: Line 216:  
|
 
|
 
|-
 
|-
−
|Microinvasive Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 225: Line 225:  
|
 
|
 
|-
 
|-
−
|Invasive lobular Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 234: Line 234:  
|
 
|
 
|-
 
|-
−
|Tubular Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 243: Line 243:  
|
 
|
 
|-
 
|-
−
|Cribriform Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 252: Line 252:  
|
 
|
 
|-
 
|-
−
|Mucinous Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 261: Line 261:  
|
 
|
 
|-
 
|-
−
|Mucinous Cystadenocarcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 270: Line 270:  
|
 
|
 
|-
 
|-
−
|Invasive Micropapillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 279: Line 279:  
|
 
|
 
|-
 
|-
−
|Carcinoma with Apocrine Differentiation||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 288: Line 288:  
|
 
|
 
|-
 
|-
−
|Metaplastic Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 297: Line 297:  
|
 
|
 
|-
 
|-
−
|Acinic Cell Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 306: Line 306:  
|
 
|
 
|-
 
|-
−
|Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach / Jun Liao
+
| ||Disease||
−
|10/12/02022
+
|
−
|11/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 +
|
 
|
 
|
−
|Hui Chen / Katherine Geiersbach
  −
|12/6/2023
  −
|2021 template added
   
|-
 
|-
−
|Secretory Carcinoma||Disease||Hui Chen / Morteza Seifi
+
| ||Disease||
−
|10/12/2022
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
   
|
 
|
−
|2021 template added
   
|-
 
|-
−
|Mucoepidermoid Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 333: Line 333:  
|
 
|
 
|-
 
|-
−
|Polymorphous Adenocarcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 342: Line 342:  
|
 
|
 
|-
 
|-
−
|Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
+
| ||Disease||
−
|8/11/2023
+
|
−
|10/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
   
|
 
|
−
|2021 template added
   
|-
 
|-
−
|Neuroendocrine Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 360: Line 360:  
|
 
|
 
|-
 
|-
−
|Neuroendocrine Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 369: Line 369:  
|
 
|
 
|-
 
|-
−
|Hamartoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 378: Line 378:  
|
 
|
 
|-
 
|-
−
|Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
−
|2021 template added
   
|-
 
|-
−
|Phyllodes Tumour||Disease||H. Evin Gulbahce / Patricija Zot / Emilie Lalonde / Katherine Geiersbach
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
−
|2021 template added
   
|-
 
|-
−
|Syringomatous Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 405: Line 405:  
|
 
|
 
|-
 
|-
−
|Nipple Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 414: Line 414:  
|
 
|
 
|-
 
|-
−
|Paget disease of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 423: Line 423:  
|
 
|
 
|-
 
|-
−
|Haemangioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 432: Line 432:  
|
 
|
 
|-
 
|-
−
|Angiomatosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 441: Line 441:  
|
 
|
 
|-
 
|-
−
|Atypical Vascular Lesions||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 450: Line 450:  
|
 
|
 
|-
 
|-
−
|Postradiation Angiosarcoma of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 459: Line 459:  
|
 
|
 
|-
 
|-
−
|Primary Angiosarcoma of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 468: Line 468:  
|
 
|
 
|-
 
|-
−
|Nodular Fasciitis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 477: Line 477:  
|
 
|
 
|-
 
|-
−
|Myofibroblastoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 486: Line 486:  
|
 
|
 
|-
 
|-
−
|Desmoid Fibromatosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 495: Line 495:  
|
 
|
 
|-
 
|-
−
|Inflammatory Myofibroblastic Tumour||Disease||Yajuan Liu
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
  −
|12/6/2023
  −
|2021 template added
   
|-
 
|-
−
|Schwannoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 513: Line 513:  
|
 
|
 
|-
 
|-
−
|Neurofibroma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 522: Line 522:  
|
 
|
 
|-
 
|-
−
|Granular Cell Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 531: Line 531:  
|
 
|
 
|-
 
|-
−
|Leiomyoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 540: Line 540:  
|
 
|
 
|-
 
|-
−
|Leiomyosarcoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 549: Line 549:  
|
 
|
 
|-
 
|-
−
|Lipoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 558: Line 558:  
|
 
|
 
|-
 
|-
−
|Angiolipoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 567: Line 567:  
|
 
|
 
|-
 
|-
−
|Liposarcoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 576: Line 576:  
|
 
|
 
|-
 
|-
−
|Pseudoangiomatous Stromal Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 585: Line 585:  
|
 
|
 
|-
 
|-
−
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 594: Line 594:  
|
 
|
 
|-
 
|-
−
|Follicular Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 603: Line 603:  
|
 
|
 
|-
 
|-
−
|Diffuse Large B-cell Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 612: Line 612:  
|
 
|
 
|-
 
|-
−
|Burkitt Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 621: Line 621:  
|
 
|
 
|-
 
|-
−
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 630: Line 630:  
|
 
|
 
|-
 
|-
−
|Gynaecomastia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 639: Line 639:  
|
 
|
 
|-
 
|-
−
|Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 648: Line 648:  
|
 
|
 
|-
 
|-
−
|Invasive Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 657: Line 657:  
|
 
|
 
|-
 
|-
−
|Metastases to the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 666: Line 666:  
|
 
|
 
|-
 
|-
−
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach
+
| ||Disease||
−
|12/6/2023
+
|
−
|3/6/2024
+
|
 
|
 
|
 
|
 
|
Line 675: Line 675:  
|
 
|
 
|-
 
|-
−
|Cowden Syndrome||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 684: Line 684:  
|
 
|
 
|-
 
|-
−
|Ataxia-Telangiectasia||Disease||Evin Gulbahce / Katherine Geiersbach
+
| ||Disease||
−
|12/11/2023
+
|
−
|3/11/2024
+
|
 +
|
 
|
 
|
 
|
 
|
−
|Katherine Geiersbach
   
|
 
|
 
|
 
|
 
|-
 
|-
−
|Li-Fraumeni Syndrome, TP53-Associated||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 702: Line 702:  
|
 
|
 
|-
 
|-
−
|Li-Fraumeni Syndrome, CHEK2-Associated||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 711: Line 711:  
|
 
|
 
|-
 
|-
−
|CDH1-Associated Breast Cancer||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 720: Line 720:  
|
 
|
 
|-
 
|-
−
|PALB2-Associated Cancers||Disease||Constance Albarracin / Katherine Geiersbach
+
| ||Disease||
−
|12/8/2023
+
|
−
|3/8/2024
+
|
 
|
 
|
 
|
 
|
Line 729: Line 729:  
|
 
|
 
|-
 
|-
−
|Peutz-Jeghers Syndrome||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 738: Line 738:  
|
 
|
 
|-
 
|-
−
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
+
| ||Disease||
 +
|
 
|
 
|
 
|
 
|
Line 745: Line 746:  
|
 
|
 
|
 
|
−
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
   
|-
 
|-
−
|Polygenic Component of Breast Cancer Susceptibility
+
|
 
|Disease
 
|Disease
 
|
 
|
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/14030"